Literature DB >> 15720817

Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.

Catherine Maillard1, Maud Jost, Maria Unni Rømer, Nils Brunner, Xavier Houard, Annabelle Lejeune, Carine Munaut, Khalid Bajou, Laurence Melen, Keld Dano, Peter Carmeliet, Norbert E Fusenig, Jean Michel Foidart, Agnès Noel.   

Abstract

Angiogenesis and tumor expansion are associated with extracellular matrix remodeling and involve various proteases such as the plasminogen (Plg)/plasminogen activator (PA) system. Recently, several experimental data have implicated the plasminogen activator inhibitor-1 (PAI-1) in tumor angiogenesis in murine systems. However, little is known about PAI-1 functions in human skin carcinoma progression. By generating immunodeficient mice (in Rag-1-/- or nude background) deleted for PAI-1 gene (PAI-1-/-), we have evaluated the impact of host PAI-1 deficiency on the tumorigenicity of two malignant human skin keratinocyte cell lines HaCaT II-4 and HaCaT A5-RT3 forming low-grade and high-grade carcinomas, respectively. When using the surface transplantation model, angiogenesis and tumor invasion of these two cell lines are strongly reduced in PAI-1-deficient mice as compared to the wild-type control animals. After subcutaneous injection in PAI-1-/- mice, the tumor incidence is reduced for HaCaT II-4 cells, but not for those formed by HaCaT A5-RT3 cells. These data indicate that PAI-1 produced by host cells is an important contributor to earlier stages of human skin carcinoma progression. It exerts its tumor-promoting effect in a tumor stage-dependent manner, but PAI-1 deficiency is not sufficient to prevent neoplastic growth of aggressive tumors of the human skin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15720817      PMCID: PMC1490321          DOI: 10.1593/neo.04406

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  37 in total

1.  Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1.

Authors:  S Stefansson; E Petitclerc; M K Wong; G A McMahon; P C Brooks; D A Lawrence
Journal:  J Biol Chem       Date:  2000-11-16       Impact factor: 5.157

2.  Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.

Authors:  G A McMahon; E Petitclerc; S Stefansson; E Smith; M K Wong; R J Westrick; D Ginsburg; P C Brooks; D A Lawrence
Journal:  J Biol Chem       Date:  2001-07-05       Impact factor: 5.157

3.  Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.

Authors:  L S Gutierrez; A Schulman; T Brito-Robinson; F Noria; V A Ploplis; F J Castellino
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

4.  Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.

Authors:  V Lambert; C Munaut; A Noël; F Frankenne; K Bajou; R Gerard; P Carmeliet; M P Defresne; J M Foidart; J M Rakic
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

5.  Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin.

Authors:  G Deng; S A Curriden; G Hu; R P Czekay; D J Loskutoff
Journal:  J Cell Physiol       Date:  2001-10       Impact factor: 6.384

6.  Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active.

Authors:  J Vakili; L Ständker; M Detheux; G Vassart; W G Forssmann; M Parmentier
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

Review 7.  New functions of stromal proteases and their inhibitors in tumor progression.

Authors:  A Noel; V Albert; K Bajou; C Bisson; L Devy; F Frankenne; E Maquoi; V Masson; N E Sounni; J M Foidart
Journal:  Surg Oncol Clin N Am       Date:  2001-04       Impact factor: 3.495

8.  Defects of basement membrane and hemidesmosome structure correlate with malignant phenotype and stromal interactions in HaCaT-Ras xenografts.

Authors:  P Tomakidi; N Mirancea; N E Fusenig; C Herold-Mende; F X Bosch; D Breitkreutz
Journal:  Differentiation       Date:  1999-06       Impact factor: 3.880

9.  Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.

Authors:  M M Mueller; W Peter; M Mappes; A Huelsen; H Steinbauer; P Boukamp; M Vaccariello; J Garlick; N E Fusenig
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

10.  High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase.

Authors:  A Boulay; R Masson; M P Chenard; M El Fahime; L Cassard; J P Bellocq; C Sautès-Fridman; P Basset; M C Rio
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

View more
  21 in total

1.  Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.

Authors:  Anne Masset; Catherine Maillard; Nor Eddine Sounni; Nathalie Jacobs; Françoise Bruyére; Philippe Delvenne; Marlene Tacke; Thomas Reinheckel; Jean-Michel Foidart; Lisa M Coussens; Agnès Noël
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

2.  Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.

Authors:  Mark D Sternlicht; Alison M Dunning; Dan H Moore; Paul D P Pharoah; David G Ginzinger; Koei Chin; Joe W Gray; Frederic M Waldman; Bruce A J Ponder; Zena Werb
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

Review 3.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

4.  PAI-1 mediates the TGF-beta1+EGF-induced "scatter" response in transformed human keratinocytes.

Authors:  Jennifer Freytag; Cynthia E Wilkins-Port; Craig E Higgins; Stephen P Higgins; Rohan Samarakoon; Paul J Higgins
Journal:  J Invest Dermatol       Date:  2010-04-29       Impact factor: 8.551

5.  Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.

Authors:  Maud Jost; Catherine Maillard; Julie Lecomte; Vincent Lambert; Marc Tjwa; Pierre Blaise; Maria-Luz Alvarez Gonzalez; Khalid Bajou; Silvia Blacher; Patrick Motte; Chantal Humblet; Marie Paule Defresne; Marc Thiry; Francis Frankenne; André Gothot; Peter Carmeliet; Jean-Marie Rakic; Jean-Michel Foidart; Agnès Noël
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

6.  Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.

Authors:  Maria U Rømer; Lise Larsen; Hanne Offenberg; Nils Brünner; Ulrik A Lademann
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

7.  Does plasminogen activator inhibitor-1 drive lymphangiogenesis?

Authors:  Françoise Bruyère; Laurence Melen-Lamalle; Silvia Blacher; Benoît Detry; Anne Masset; Julie Lecomte; Vincent Lambert; Catherine Maillard; Gunilla Høyer-Hansen; Leif R Lund; Jean-Michel Foidart; Agnès Noël
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

8.  PAI-1 Regulates the Invasive Phenotype in Human Cutaneous Squamous Cell Carcinoma.

Authors:  Jennifer Freytag; Cynthia E Wilkins-Port; Craig E Higgins; J Andrew Carlson; Agnes Noel; Jean-Michel Foidart; Stephen P Higgins; Rohan Samarakoon; Paul J Higgins
Journal:  J Oncol       Date:  2010-03-01       Impact factor: 4.375

9.  TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1.

Authors:  Cynthia E Wilkins-Port; Qunhui Ye; Joseph E Mazurkiewicz; Paul J Higgins
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

10.  Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.

Authors:  Zhong Dong; Allen D Saliganan; Hong Meng; Sanaa M Nabha; Aaron L Sabbota; Shijie Sheng; R Daniel Bonfil; Michael L Cher
Journal:  Neoplasia       Date:  2008-05       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.